These findings underscore the need for strengthened infection prevention in ICU settings and a careful review of empirical antibiotic use policies, particularly regarding the use of agents such as carbapenems, colistin, cefiderocol, and novel beta-lactam–beta-lactamase inhibitor combinations, which are now considered last-resort options for treating multidrug-resistant Gram-negative infections [31,32,33]. This evidence concerns the gene LACTB and infection.